Results for tag: "Pertussis Vaccine"

Within the context of vaccine markets, the pertussis vaccine, commonly known as the whooping cough vaccine, plays a crucial role in public health due to the highly infectious nature of the Bordetella pertussis bacterium. The vaccine is often administered in combination with tetanus and diphtheria vaccines, known as the DTaP vaccine for children and the Tdap booster for adolescents and adults. Immunization initiatives have focused on protecting infants and children, who are most vulnerable to the severe complications of pertussis. The immunization schedule for the pertussis vaccine typically involves a series of shots starting from the age of two months. Research and development in this market are driven by the need for more efficacious vaccines with fewer side effects, and efforts to improve coverage and access, especially in underserved regions. Some of the prominent companies participating in the pertussis vaccine market include Sanofi Pasteur, which produces a range of pertussis vaccines for various age groups; GlaxoSmithKline, the maker of another commonly used DTaP vaccine; and Merck & Co., which also offers vaccines that protect against pertussis among other infectious diseases. Other key players in the market encompass Pfizer and various regional pharmaceutical firms that contribute to the production and distribution of these vaccines. Show Less Read more